| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9622340 | UPSHER SMITH LABS | Flexible circuit board and method for manufacturing same |
Feb, 2034
(9 years from now) | |
| US9295675 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(9 years from now) | |
| US9662340 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(9 years from now) | |
| US8785426 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(9 years from now) | |
Vogelxo is owned by Upsher Smith Labs.
Vogelxo contains Testosterone.
Vogelxo has a total of 4 drug patents out of which 0 drug patents have expired.
Vogelxo was authorised for market use on 04 June, 2014.
Vogelxo is available in gel, metered;transdermal, gel;transdermal dosage forms.
Vogelxo can be used as method for transdermal delivery of testosterone.
The generics of Vogelxo are possible to be released after 11 February, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2017 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 04 June, 2014
Treatment: Method for transdermal delivery of testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
More Information on Dosage
VOGELXO family patents
